Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001640455-21-000147
Filing Date
2021-11-04
Accepted
2021-11-04 16:11:00
Documents
63
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q jnce-20210930.htm   iXBRL 10-Q 1198993
2 EX-31.1 jnce09302021exhibit311.htm EX-31.1 9185
3 EX-31.2 jnce09302021exhibit312.htm EX-31.2 9193
4 EX-32.1 jnce09302021exhibit321.htm EX-32.1 7515
  Complete submission text file 0001640455-21-000147.txt   5405479

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT jnce-20210930.xsd EX-101.SCH 33376
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT jnce-20210930_cal.xml EX-101.CAL 48591
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT jnce-20210930_def.xml EX-101.DEF 161036
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT jnce-20210930_lab.xml EX-101.LAB 465823
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT jnce-20210930_pre.xml EX-101.PRE 300322
10 EXTRACTED XBRL INSTANCE DOCUMENT jnce-20210930_htm.xml XML 915868
Mailing Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 857-259-3840
Jounce Therapeutics, Inc. (Filer) CIK: 0001640455 (see all company filings)

EIN.: 454870634 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37998 | Film No.: 211380032
SIC: 2836 Biological Products, (No Diagnostic Substances)